11.88
+2.77%
Close of 9 Nov 2026, in CAD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Bausch Health Companies
Its shares trade on Toronto Stock Exchange under the ticker BHC.TO. It has been listed since 20 September 1994. In the fiscal year to 31 December 2025, it reported revenue of $10.45bn and net income of $159.7m. At that date it held total assets of $26.32bn and shareholders' equity of −$553.0m.
Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. The company is headquartered in Laval, Quebec. The company primarily develops products in the therapeutic areas of eye health, gastroenterology and dermatology. Its dermatology products treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis and other dermatoses. The company also offers a selection of aesthetic medical devices that address a variety of conditions, including facial wrinkles, acne, pigmentation conditions and laser hair removal, among others. The gastrointestinal (GI) segment offers products that treat GI and hepatologic conditions, including hepatic encephalopathy, irritable bowel syndrome with diarrhea and ulcerative colitis, among others. Its eye health products are marketed in the following categories: Contact Lens, Pharmaceutical Products and Surgical.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 20 Sept 1994
- Employees
- 21,600
- Website
- bauschhealth.com ↗
Leadership
Pay as last reported
- Mr. John PaulsonIndependent Non-Executive Chairman of the Board$783,736
- Mr. Thomas AppioChief Executive Officer, Director, since 2016$16.2m
- Mr. Jean-Jacques CharhonExecutive Vice President, Chief Financial Officer$4.3m
- Ms. Seana CarsonExecutive Vice President, General Counsel$4.0m
- Ms. Aimee LenarExecutive Vice President, US Pharma$2.0m
- Mr. Steven LeeSenior Vice President, Controller, Chief Accounting Officer
- Mr. Michael GoettlerDirector
- Ms. Sandra LeungDirector
- Mr. Christian GarciaIndependent Director$329,166
- Ms. Sarah KavanaghIndependent Director$729,986
- Mr. Frank LeeIndependent Director$330,750
- Dr. Richard MulliganIndependent Director$382,500
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 51
- Environment
- 19
- Social
- 63
- Governance
- 70
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Bausch Health Companies Inc. boasts a strong product portfolio, offering a wide range of pharmaceutical and healthcare products, including prescription drugs, contact lenses, and over-the-counter medications. The company's diverse product offerings provide a competitive edge in the healthcare industry.
- Bausch Health has established a solid global presence, with a strong market share and distribution networks in multiple countries. This global reach allows the company to tap into various markets, reducing dependency on specific regions and diversifying its revenue streams.
- The company has a dedicated research and development (R&D) team, continuously working on innovation and new product development. This emphasis on R&D enables Bausch Health to stay at the forefront of healthcare advancements, catering to evolving customer needs and remaining competitive in the market.
Weaknesses
- Bausch Health has faced scrutiny and legal challenges in the past, affecting its reputation and resulting in financial penalties. These legal issues have hindered the company's growth potential and damaged its brand image, requiring significant efforts to regain trust among stakeholders.
- The company heavily relies on a few key products for a significant portion of its revenue. This overreliance on specific products exposes Bausch Health to the risk of patent expiration, market saturation, or competition, impacting its financial performance in case of any setbacks.
- Bausch Health has a considerable amount of debt, which may limit its financial flexibility. The need to make interest and principal repayments can restrict the company's ability to invest in R&D or pursue potential strategic opportunities for growth.
Opportunities
- The aging global population presents a promising opportunity for Bausch Health. With an increasing number of elderly individuals requiring healthcare products and services, the company can expand its offerings to cater to this growing market segment, providing a potential avenue for revenue growth.
- Bausch Health can explore strategic partnerships and acquisitions to enhance its product portfolio or expand into new markets. Collaborations with innovative startups or established healthcare companies can bring in new expertise, technologies, or geographies, driving competitive advantage and market positioning.
- The growing global focus on healthcare and wellness creates opportunities for Bausch Health to develop and market products that align with consumer demands. Investing in research and development efforts that address emerging healthcare trends can position the company for success in a rapidly evolving industry.
Threats
- Intense competition within the pharmaceutical and healthcare industry poses a threat to Bausch Health. Rival companies may launch competitive products, leading to price wars, reduced market share, or decreased profitability. Staying ahead of the competition requires continuous innovation and effective marketing strategies.
- Changes in government regulations or healthcare policies can significantly impact Bausch Health's operations and market access. Shifts in regulatory frameworks, reimbursement policies, or drug approvals may create barriers or disrupt existing revenue streams, requiring agility in adapting to new rules or guidelines.
- Economic downturns or fluctuations can affect consumer spending on healthcare products. During times of financial instability, individuals may prioritize essential needs, leading to reduced demand for non-essential healthcare items. Bausch Health needs to anticipate and mitigate such risks to maintain stable financial performance.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.